Seattle Genetics Rises On CEO's Appearance On CNBC (SGEN)
Shares of Seattle Genetics (NASDAQ: SGEN) have surged during Tuesday's trading session after the company's CEO appeared on CNBC earlier in the day. The stock has gained 4.24% to $16.49 on heavy volume. More than 2.53 million SGEN shares have already changed hands compared to a daily average of less than 1 million.
Seattle Genetics, Inc. (Seattle Genetics) is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.